RxDoctor Payments DataLook up a doctor →

Amy Case, MD

Pulmonary Disease · Austell, GANPI 1467664466

Payments from drug & device makers

$1,500,131in general payments, 2019–2025

Across 395 payments — averaging $3797.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$514K
  • Boehringer Ingelheim$474K
  • Regeneron$149K
  • Roche Products Limited$139K
  • Kadmon Corporation LLC$108K
  • Genentech, Inc.$40K
  • plus $75K from 24 others
$2,826in research payments, 2019–2025

Across 2 payments — averaging $1412.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$3K

What the payments were for

  • Consulting fees$7,40018%
  • Speaking & faculty fees$29,14072%
  • Travel & lodging$1,6344%
  • Food & beverage$2,1975%
  • Education$280%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,500,131 in reported general payments places this provider in the 95th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$69,951
Medicare patients
198
Services billed
970

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate117$1,465,366
Pirfenidone33$130,093
Trelegy ElliptaFluticasone/Umeclidin/Vilanter63$51,405
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr31$17,318
Breo ElliptaFluticasone/Vilanterol33$16,907
SymbicortBudesonide/Formoterol Fumarate21$5,548
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$2,189
Albuterol Sulfate HfaAlbuterol Sulfate30$1,340
Ventolin HfaAlbuterol Sulfate19$989
Prednisone88$512
Esomeprazole Magnesium15$337
Azithromycin16$323
Omeprazole17$321
Montelukast Sodium18$190
Fluticasone Propionate18$176

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev$473,684$1,465,366117 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$251$85,630127 claims
AstraZenecaSymbicort$43$5,54821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Austell

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →